ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.13 by 22.14 percent. This is a 20 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $264.566 million which beat the analyst consensus estimate of $262.414 million by 0.82 percent. This is a 9.34 percent increase over sales of $241.963 million the same period last year.